Parenclitic networks for predicting ovarian cancer
暂无分享,去创建一个
John F. Timms | Alexey Zaikin | Usha Menon | Harry J. Whitwell | Oleg Blyuss | U. Menon | A. Zaikin | J. Timms | O. Blyuss | H. Whitwell
[1] N. Johnson. Two large randomised trials show ovarian cancer screening has minimal impact on survival , 2018, BJOG : an international journal of obstetrics and gynaecology.
[2] L. Ding,et al. Midkine derived from cancer-associated fibroblasts promotes cisplatin-resistance via up-regulation of the expression of lncRNA ANRIL in tumour cells , 2017, Scientific Reports.
[3] F. Korner‐Nievergelt,et al. The earth is flat (p > 0.05): significance thresholds and the crisis of unreplicable research , 2017, PeerJ.
[4] L. Miller,et al. Conservation of immune gene signatures in solid tumors and prognostic implications , 2016, BMC Cancer.
[5] M. Zanin. Using complex networks for refining survival prognosis in prostate cancer patient , 2016, F1000Research.
[6] Y. Naomoto,et al. Novel Midkine Inhibitor iMDK Inhibits Tumor Growth and Angiogenesis in Oral Squamous Cell Carcinoma. , 2016, Anticancer research.
[7] D. Oram,et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial , 2016, The Lancet.
[8] J. Chester,et al. Personalised cancer medicine , 2015, International journal of cancer.
[9] Christian Pilarsky,et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer , 2015, Nature.
[10] Iosif Meyerov,et al. Parenclitic Network Analysis of Methylation Data for Cancer Identification , 2015, PloS one.
[11] Edmond J. Breen,et al. A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes’ stages A-D colorectal cancers , 2015, Clinical Proteomics.
[12] Bernard Rachet,et al. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study , 2015, The Lancet.
[13] G. von Heijne,et al. Tissue-based map of the human proteome , 2015, Science.
[14] Jingyan Xie,et al. Midkine as a potential diagnostic marker in epithelial ovarian cancer for cisplatin/paclitaxel combination clinical therapy. , 2015, American journal of cancer research.
[15] Massimiliano Zanin,et al. Parenclitic networks: uncovering new functions in biological data , 2014, Scientific Reports.
[16] A. Wellstein,et al. Expression of a Secreted Fibroblast Growth Factor Binding Protein-1 (FGFBP1) in Angioproliferative Kaposi Sarcoma , 2014, Journal of AIDS & clinical research.
[17] J. Stenvang,et al. Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability , 2014, PloS one.
[18] M. Akbari,et al. Granzyme H Serum Levels Variations with Both Reproductive Hormone Receptors, and Related Hormone Receptors in Breast Cancer Patients , 2014, Iranian journal of cancer prevention.
[19] S. Buys,et al. Oral contraceptive and reproductive risk factors for ovarian cancer within sisters in the breast cancer family registry , 2014, British Journal of Cancer.
[20] Robert Brown,et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling , 2012, Oncogene.
[21] Sudhir Srivastava,et al. Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens , 2011, Cancer Prevention Research.
[22] D Timmerman,et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm , 2011, British Journal of Cancer.
[23] T. Muramatsu. Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases , 2010, Proceedings of the Japan Academy. Series B, Physical and biological sciences.
[24] Jinping Li,et al. HE4 as a biomarker for ovarian and endometrial cancer management , 2009, Expert review of molecular diagnostics.
[25] Jason Gunn,et al. Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. , 2008, The Journal of clinical investigation.
[26] Lucas Antiqueira,et al. Analyzing and modeling real-world phenomena with complex networks: a survey of applications , 2007, 0711.3199.
[27] Francis S. Collins,et al. Mapping the cancer genome , 2007 .
[28] A. Maitra,et al. Expression of a fibroblast growth factor-binding protein during the development of adenocarcinoma of the pancreas and colon. , 2006, Cancer research.
[29] H. Roberts. Gynaecological cancer and the contraceptive pill , 2004 .
[30] Michèl Schummer,et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. , 2003, Cancer research.
[31] Joshua J. Millspaugh,et al. Effects of sample size on kernel home range estimates , 1999 .
[32] P. J. Green,et al. Density Estimation for Statistics and Data Analysis , 1987 .
[33] J. Dungan. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm , 2011 .
[34] Steven J Skates,et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. , 2009, Gynecologic oncology.
[35] R. Bast,et al. The CA 125 tumour-associated antigen: a review of the literature. , 1989, Human reproduction.